Similarly, bispecific antibodies targeting CD40 or CD1d have shown success in preclinical models of hematological malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) [97,98]. Here, CD1D is linked to Miyoshi myopathy.